In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease
Public Health,Science,FDA,DNA,CRISPR
From the Center
AllSides Media Bias Rating: Center
The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.
The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.
Check for Bias
The AI-powered AllSides Bias Checker instantly reveals the bias of a news article. Tap the button to use.
AllSides Picks
Red Blue Translator
FDA (U.S. Food & Drug Administration)
Red Blue Translator
Affordable Care Act
Bias
Bloomberg Bias Rating Moves From Lean Left to Center: 2026 AllSides Update
AllSides Staff
July 21st, 2026
